January 9th - 2012

Future presentations at the EAU 2012

Pelvipharm at the EAU (European Association of Urology) in Paris, France, 24 - 28 February 2012.

Pelvipharm will present 3 posters:

• "Minimal effective dose (MED) of onabotulinumtoxinA (onaBoNT-A) and abobotulinumtoxinA (aboBoNT-A) in a rat model of neurogenic detrusor overactivity (NDO)"
        D. Behr-Roussel, S. Oger, B. Pignol, E. Pham, A. Le Maux, P.E. Chabrier, P. Picaut, S. Caisey, S. Compagnie, F. Giuliano, P. Denys.
• "Evidence for a functional role of connexin 43 and 45 in human neurogenic detrusor overactivity"
       V. Phe, D. Behr-Roussel, S. Oger, E. Chartier-Kastler, T. Ghoneim, T. Lebret, G. Karsenty, E. Comperat, P. Camparo, P. Validire, F. Giuliano.
• "Spontaneous contractile activity of human neurogenic bladder strips: Can we predict a correlation with between clinical factors, urodynamics and histological features?"
        V. Phe, S. Oger, D. Behr-Roussel, P. Denys, E. Comperat, F. Giuliano, E. Chartier-Kastler.
  
  François Giuliano will present 1 poster:
  
  
• "Effects of tadalafil (TAD) or tamsulosin (TAM) on erectile function in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): Results from a multicenter, double-blind, randomized, placebo (PLA)-controlled 12-week study"
        F. Giuliano; M. Oelke; V. Mirone; S. Watts; D. Cox; L. Viktrup
  
  

Delphine Behr-Roussel will chair the session 40 : "Sexual dysfunction: Basic research"

Please come and see us, we will be happy to discuss our results with you and potential applications for you.